abrdn plc Has $13.92 Million Stake in Kenvue Inc. (NYSE:KVUE)

abrdn plc lessened its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 7.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 654,337 shares of the company's stock after selling 53,710 shares during the quarter. abrdn plc's holdings in Kenvue were worth $13,921,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Childress Capital Advisors LLC boosted its position in shares of Kenvue by 11.4% in the 4th quarter. Childress Capital Advisors LLC now owns 16,090 shares of the company's stock worth $344,000 after purchasing an additional 1,642 shares during the last quarter. Renaissance Capital LLC boosted its holdings in Kenvue by 9.3% during the fourth quarter. Renaissance Capital LLC now owns 723,592 shares of the company's stock worth $15,449,000 after buying an additional 61,330 shares during the last quarter. One Wealth Advisors LLC boosted its holdings in Kenvue by 31.4% during the fourth quarter. One Wealth Advisors LLC now owns 12,131 shares of the company's stock worth $259,000 after buying an additional 2,897 shares during the last quarter. Willis Investment Counsel grew its position in shares of Kenvue by 0.6% during the 4th quarter. Willis Investment Counsel now owns 888,983 shares of the company's stock worth $18,980,000 after buying an additional 5,231 shares during the period. Finally, U.S. Capital Wealth Advisors LLC raised its position in shares of Kenvue by 5.6% in the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 29,298 shares of the company's stock valued at $626,000 after acquiring an additional 1,551 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

Kenvue stock traded up $0.35 during trading hours on Tuesday, reaching $20.93. 10,921,780 shares of the stock were exchanged, compared to its average volume of 12,761,109. The stock has a 50 day moving average of $21.46 and a two-hundred day moving average of $22.02. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market cap of $40.13 billion, a P/E ratio of 39.49, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts expect that Kenvue Inc. will post 1.05 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.92%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue's dividend payout ratio (DPR) is 154.72%.

Analyst Ratings Changes

Several analysts recently commented on the company. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Barclays reduced their price target on Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a "buy" rating to a "hold" rating and lowered their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 15th. Finally, Piper Sandler raised Kenvue from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $21.00 to $26.00 in a research report on Monday, January 6th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.